The E345R hexamerization mutation can facilitate higher agonism independent of FcγRIIB cross-linking, which may equip antibody with defined therapeutic activity regardless of FcγR expression levels in the local microenvironment, particularly an advantage for those tumor microenvironments with low levels of infiltration of FcγR expressing cells. Here, FCGR2A is linked to neoplasm.